Alpha 2.0
Login Register
» Authors » Pablo Garcia-Manau

Pablo Garcia-Manau

Explore the profile of Pablo Garcia-Manau including associated specialties, affiliations and a list of published articles. Areas
Snapshot
Articles 23
Citations 108
Followers 0
Related Specialties
Gynecology & Obstetrics
General Medicine
Molecular Biology
Top 10 Co-Authors
Elena Carreras
Manel Mendoza
Erika Bonacina
Berta Serrano
Nerea Maiz
Anna Maroto
Angels Vives
Mireia Armengol-Alsina
Carlota Rodo
Eva Lopez-Quesada
Published In
Acta Obstet Gynecol Scand
Int J Gynaecol Obstet
BJOG
BMC Pregnancy Childbirth
J Gynecol Obstet Hum Reprod
Affiliations
Soon will be listed here.
Recent Articles
1.
Angiogenic factors versus fetomaternal Doppler for fetal growth restriction at term: an open-label, randomized controlled trial
Garcia-Manau P, Bonacina E, Martin-Alonso R, Martin L, Palacios A, Sanchez-Camps M, et al.
Nat Med . 2025 Jan; PMID: 39775039
Small fetuses, with estimated fetal weight (EFW) below the tenth percentile, are classified as fetal growth restriction (FGR) or small for gestational age (SGA) based on prenatal ultrasound. FGR fetuses...
2.
Placental growth factor at 24-28 weeks for aspirin discontinuation in pregnancies at high risk for preterm preeclampsia: Post hoc analysis of StopPRE trial
Ricart M, Bonacina E, Garcia-Manau P, Lopez M, Caamina S, Vives A, et al.
Acta Obstet Gynecol Scand . 2024 Aug; 103(11):2273-2280. PMID: 39171611
Introduction: This study aims to evaluate the safety of discontinuing aspirin treatment at 24-28 weeks in women at high risk after first-trimester combined screening for preeclampsia (PE) and normal placental...
3.
Clinical effectiveness of routine first-trimester combined screening for pre-eclampsia in Spain with the addition of placental growth factor
Garcia-Manau P, Bonacina E, Serrano B, Caamina S, Ricart M, Lopez-Quesada E, et al.
Acta Obstet Gynecol Scand . 2023 Oct; 102(12):1711-1718. PMID: 37814344
Introduction: Pre-eclampsia affects 2%-8% of pregnancies and is one of the leading causes of maternal and perinatal morbidity and mortality. First-trimester screening using an algorithm that combines maternal characteristics, mean...
4.
Mid-trimester uterine artery Doppler for aspirin discontinuation in pregnancies at high risk for preterm pre-eclampsia: Post-hoc analysis of StopPRE trial
Bonacina E, Garcia-Manau P, Lopez M, Caamina S, Vives A, Lopez-Quesada E, et al.
BJOG . 2023 Aug; 131(3):334-342. PMID: 37555464
Objective: To assess whether aspirin treatment can be discontinued in pregnancies with normal uterine artery pulsatility index (≤90th percentile) at 24-28 weeks. Design: Post-hoc analysis of a clinical trial. Setting:...
5.
Fetal abdominal cysts: Predicting adverse outcomes
Garcia-Aguilar P, Maiz N, Rodo C, Garcia-Manau P, Arevalo S, Molino J, et al.
Acta Obstet Gynecol Scand . 2023 May; 102(7):883-890. PMID: 37194337
Introduction: The primary aim of the study was to identify risk factors associated with fetal or neonatal loss, neonatal morbidity, and the need for surgery in fetuses diagnosed with an...
6.
Aspirin Discontinuation at 24 to 28 Weeks' Gestation in Pregnancies at High Risk of Preterm Preeclampsia: A Randomized Clinical Trial
Mendoza M, Bonacina E, Garcia-Manau P, Lopez M, Caamina S, Vives A, et al.
JAMA . 2023 Feb; 329(7):542-550. PMID: 36809321
Importance: Aspirin reduces the incidence of preterm preeclampsia by 62% in pregnant individuals at high risk of preeclampsia. However, aspirin might be associated with an increased risk of peripartum bleeding,...
7.
Usefulness of angiogenic factors in prenatal counseling of late-onset fetal growth-restricted and small-for-gestational-age gestations: a prospective observational study
Hurtado I, Bonacina E, Garcia-Manau P, Serrano B, Armengol-Alsina M, Mendoza M, et al.
Arch Gynecol Obstet . 2022 Nov; 308(5):1485-1495. PMID: 36401095
Objectives: To create a predictive model including biomarkers and evaluate its ability to predict adverse perinatal outcomes in late-onset small fetuses, ultimately helping to provide individualized counseling at the time...
8.
Transplantation of Human-Fetal-Spinal-Cord-Derived NPCs Primed with a Polyglutamate-Conjugated Rho/Rock Inhibitor in Acute Spinal Cord Injury
Giraldo E, Bonilla P, Mellado M, Garcia-Manau P, Rodo C, Alastrue A, et al.
Cells . 2022 Oct; 11(20). PMID: 36291170
Neural precursor cell (NPC) transplantation represents a promising therapy for treating spinal cord injuries (SCIs); however, despite successful results obtained in preclinical models, the clinical translation of this approach remains...
9.
The Fetal Growth Restriction at Term Managed by Angiogenic Factors Versus Feto-Maternal Doppler (GRAFD) Trial to Avoid Adverse Perinatal Outcomes: Protocol for a Multicenter, Open-Label, Randomized Controlled Trial
Garcia-Manau P, Mendoza M, Bonacina E, Martin-Alonso R, Martin L, Palacios A, et al.
JMIR Res Protoc . 2022 Oct; 11(10):e37452. PMID: 36222789
Background: Fetal smallness affects 10% of pregnancies. Small fetuses are at a higher risk of adverse outcomes. Their management using estimated fetal weight and feto-maternal Doppler has a high sensitivity...
10.
Confirmation of preeclampsia-like syndrome induced by severe COVID-19: an observational study
Serrano B, Bonacina E, Garcia-Ruiz I, Mendoza M, Garcia-Manau P, Garcia-Aguilar P, et al.
Am J Obstet Gynecol MFM . 2022 Oct; 5(1):100760. PMID: 36195282
Background: Since the outbreak of the COVID-19 pandemic, some studies have reported an increased preeclampsia incidence in pregnant women with SARS-CoV-2 infection. Several explanations for this association have been proposed,...